FRTX vs. TTNP, CELZ, TCON, PALI, FNCH, KRBP, GMDAQ, ALBT, NSTGQ, and ELOX
Should you be buying Fresh Tracks Therapeutics stock or one of its competitors? The main competitors of Fresh Tracks Therapeutics include Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), TRACON Pharmaceuticals (TCON), Palisade Bio (PALI), Finch Therapeutics Group (FNCH), Kiromic BioPharma (KRBP), Gamida Cell (GMDAQ), Avalon GloboCare (ALBT), NanoString Technologies (NSTGQ), and Eloxx Pharmaceuticals (ELOX). These companies are all part of the "biological products, except diagnostic" industry.
Titan Pharmaceuticals (NASDAQ:TTNP) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.
Fresh Tracks Therapeutics has a net margin of -91.29% compared to Fresh Tracks Therapeutics' net margin of -2,014.71%. Titan Pharmaceuticals' return on equity of -60.83% beat Fresh Tracks Therapeutics' return on equity.
Titan Pharmaceuticals received 335 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 56.97% of users gave Titan Pharmaceuticals an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote.
In the previous week, Titan Pharmaceuticals had 5 more articles in the media than Fresh Tracks Therapeutics. MarketBeat recorded 5 mentions for Titan Pharmaceuticals and 0 mentions for Fresh Tracks Therapeutics. Fresh Tracks Therapeutics' average media sentiment score of 0.27 beat Titan Pharmaceuticals' score of 0.00 indicating that Titan Pharmaceuticals is being referred to more favorably in the media.
31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. 24.9% of Titan Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Titan Pharmaceuticals has higher earnings, but lower revenue than Fresh Tracks Therapeutics.
Titan Pharmaceuticals has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.
Summary
Titan Pharmaceuticals beats Fresh Tracks Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Fresh Tracks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresh Tracks Therapeutics Competitors List
Related Companies and Tools
